Absci Corporation

Healthcare · Biotechnology · United States

Last price 11.13 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.91B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Ket...